Global Community
Our community narratives are driven by numbers and valuation.
Community Investing Ideas
Global Weekly Picks
KBC Group (ENXTBR:KBC) Valuation Deep-Dive: Why Dividend and Book Value Models Point in Opposite Directions.
KBC Group (ENXTBR:KBC) Valuation Deep-Dive: Why Dividend and Book Value Models Point in Opposite Directions. Current Share Price: €120.10 (as of July 20, 2026) Dividend Discount Model (DDM): €126.41 (Envelope: €90.27 – €220.03) Residual Income Model (RIM): €83.18 (Envelope: €76.83 – €89.98) Market Relative Cross-Check: €116.94 Confluence Zone: None (The two intrinsic model ranges do not overlap) Executive Summary & Core Findings Evaluating financial institutions like KBC Group NV (ENXTBR:KBC) requires a tailored valuation framework.Read more
QXO aims for $24B revenue by 2031 with AI-driven margin expansion (Priced for good execution)
QXO is trying to roll up the building-products supply chain by buying competitors and then using software to tighten pricing, cut waste, and keep the right items in stock. The big question is whether that playbook can overcome a messy share and payout setup that could leave everyday shareholders with less of the upside.Read more
For a quality compounder with intact long-term fundamentals this can represent a favorable risk/reward entry
Zoetis (ZTS) is the world's largest pure-play animal health company (spun off from Pfizer), focused on medicines, vaccines, diagnostics, and wellness products for both companion animals and livestock. Why the stock is attractive 1.Read more
NOW is an established SAAS positioned for accelerated growth over the next 5 years.
ServiceNow looks like it’s getting a new burst of demand as companies lean harder on its tools to run day-to-day work and put AI to practical use. The business also pushes deeper into tightly regulated customers and new security areas, but the big question is whether today’s excitement can keep turning into lasting sales growth.Read more
Dato’ Ng Yan Cheng Perjelaskan Pendahuluan RM89.55 Juta Bagi Menyokong Kewangan Syarikat
PRG Holdings’ biggest shareholder says he has been keeping the company going through tough times by funding day-to-day needs like staff pay and other obligations when business cash wasn’t enough. He argues the support has been misunderstood and warns that if this backstop disappears, the company’s ability to keep operating could be tested.Read more
Sonic Healthcare is poised for large upside as margins recover
Sonic Healthcare runs a huge network of medical testing and imaging services, and the key question is whether recent weakness is just a rough patch rather than a lasting problem. If demand steadies and cost pressures cool, profits could rebound even without rapid sales growth—but debt levels and healthcare payment rules remain important watch‑outs.Read more
Income Focused ARREIT
Amanah Raya REIT is starting to look stronger again after a long slump, with signs of fresh buying interest and a return to profit. But thin trading activity and uncertainty across commercial property mean the upside may come slowly, and a reversal could still catch income investors off guard.Read more
This company finances 1 out of 10 apartment builds in Australia. Many investors have never heard of it
Qualitas steps in where Australian banks increasingly won’t, funding apartment and commercial property projects and getting paid in several ways as those deals are made and managed. It’s grown quickly and is now pushing into Europe, but the same real-estate cycle, tighter rules, or stumbles on its expansion could test how durable that growth really is.Read more
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
DuChemBio (KOSDAQ: 176750): Radiopharmaceutical Monopoly, Radio DNS Labs Merger, and the 6-Month RLT Time Lag 1. The Narrative Origin: From Diagnostic Monopoly to Novartis-Driven RLT Powerhouse DuChemBio is South Korea’s undisputed leader in radiopharmaceuticals.Read more
